KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Common Equity (2016 - 2025)

Historic Common Equity for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $17.3 billion.

  • Vertex Pharmaceuticals' Common Equity rose 1079.85% to $17.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 billion, marking a year-over-year increase of 1079.85%. This contributed to the annual value of $16.4 billion for FY2024, which is 665.97% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Common Equity stood at $17.3 billion, which was up 1079.85% from $17.2 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Common Equity ranged from a high of $18.5 billion in Q1 2024 and a low of $9.0 billion during Q1 2021
  • Moreover, its 5-year median value for Common Equity was $14.8 billion (2024), whereas its average is $14.1 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Common Equity surged by 3897.83% in 2021 and then tumbled by 1105.49% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Common Equity stood at $10.1 billion in 2021, then skyrocketed by 37.75% to $13.9 billion in 2022, then grew by 26.36% to $17.6 billion in 2023, then decreased by 6.66% to $16.4 billion in 2024, then grew by 5.54% to $17.3 billion in 2025.
  • Its Common Equity was $17.3 billion in Q3 2025, compared to $17.2 billion in Q2 2025 and $16.5 billion in Q1 2025.